| INTRODUCTION
All levels of asthma severity show evidence of airway inflammation, with both eosinophils and neutrophils contributing to asthmatic inflammatory patterns. [1] [2] [3] [4] [5] [6] We have reported that asthma subjects, having combined increases in both sputum eosinophils and neutrophils, had the lowest lung function, worse asthma control, increased symptoms and healthcare utilization. 7 Unsupervised cluster analysis in the Severe Asthma Research Program (SARP) including sputum and blood eosinophil and neutrophil percentages, showed sputum neutrophils associated with more severe asthma. 6 However, most studies in asthma have focused on eosinophils and Th2 inflammation 8 with little consideration of the potential role of neutrophils, 1, 9, 10 Th1 and Th17 inflammation pathways 7, 11, 12 Investigation of inflammatory pathology underlying asthma has shifted to molecular components. [13] [14] [15] [16] [17] [18] However, the list for molecular biomarkers associated with either innate or adaptive immune response is extensive. 13, [19] [20] [21] Th2 and subset Th9 cells primarily express IL-4, IL-5, IL-9 and IL-13 through STAT6
and GATA3 regulation in response to IL-4, whereas Th1 cells express
IFN-c, IL-12 and IL-10 family members, IL-22 and IL-26, through STAT4
and T-bet regulation in response to IL-12 and IFN-c; thus, both Th1 and Th2 have positive autoregulatory reinforcement. 22 Th17 inflammation is distinct from either Th1 or Th2 and is suppressed by IFN-c and IL-4, but responds to TGF-b and IL-6 stimulation. 13 An approach to investigating airway inflammation in asthma is through use of broad-spectrum multiplex protein assay, which allows assessment of relationships, both protein-cell and protein-protein associations. Moreover, this approach avoids reliance on measures of mRNA which lack linear association with actual protein synthesized. 23 Although several recent reports have examined gene expression patterns in sputum and bronchial epithelial samples from subjects with severe asthma, these have included more limited information on corresponding protein analyses. [24] [25] [26] [27] One report from U-BIOPRED, examining protein differences between 4 clinically identified cluster groups, found 9 differentially abundant sputum proteins in more severe clusters compared to moderate, well-controlled asthma with normal FEV1. 28 However, the 1 cluster group with greatest number of differentially abundant proteins was characterized by 16 -packyear smoking history which may influence and contribute to these elevated proteins. Biomarkers observed to be associated with clinical phenotypic subgroups in asthma or specific cellular inflammation may be useful to predict response to steroids or newly developed biologic therapies. Studies in mice suggest that steroid resistant inflammation may be mediated by Th17 inflammation, 29 and that neutralization of IL-22, a Th17-associated cytokine, attenuates pro-inflammatory response and lung function decrements elicited by A fumigatus conidia in mice sensitized to this allergen. 30 From these observations, we hypothesize that different mediator and cell interactions may exist in specific subgroups of patients with asthma, for example, those with mild, moderate or severe asthma, and that release of inflammatory proteins is associated with increased cell influx into the airways, reflecting underlying Th1, Th2, Th9 and Th17 inflammation, or combinations of these.
To address these hypotheses, we measured 75 cytokines, chemokines and growth factors, representing a broad range of airway inflammatory proteins, examined differences in defined subgroups of mild, moderate and severe asthma, and tested for correlations with increased cell constituents in sputum. In addition,
we performed factor analyses to identify interactive group associations among increased cytokines, chemokines and growth factors.
| METHODS
Patients with mild to severe asthma were comprehensively character- 33 ) or not severe asthma (N = 63, mild asthmatics, and N = 57 moderate asthmatics not meeting "severe" criteria). 31, 32 Demographics and clinical characteristics for these subjects corresponded to those previously reported for subjects from all SARP sites 31 (Table 1) .
| Sputum induction and processing
The sputum induction method was adopted from the NHLBI Asthma Clinical Research Network 34 and used in SARP. 6, 7 The induction and processing are described in greater detail in the supporting information. Sputum was induced and processed immediately following spirometry. Cell cytospins were stained for differential counts of at least 500 non-squamous cells per subject slide. Cell-free supernatants were aliquoted and stored at À80 o before use in Luminex analyses (see below). Both cytokines and specific cell types were expressed per mL of total sputum sample obtained.
| Inflammatory cytokine assay
Cell-free sputum supernatants were assayed for 75 different inflammatory protein concentrations using Milliplex Human Cytokine/Chemokine Panels I, II and III (catalogue numbers HCYTOMAG-60K, HCYP2MAG-62K and HCYP3MAG-63K, respectively, Merck Millipore) as previously described. 35 Standards for determination of linear curve plus 2 control samples representing high and low levels for each cytokine/chemokine were included in each assay. Initial analysis considered the number of subjects with measurable levels for each cytokine, chemokine or growth factor; if more than 100 subjects' samples had undetectable or out-of-range values, further association with specific cell counts in multiple linear regression models was not explored (the 11 cytokines excluded for all subjects are listed in Table S2 ). 
| Statistics

| RESULTS
Subject demographics and clinical characteristics for the whole cohort and the subgroups with mild, moderate or severe asthma are presented in Table 1 . There were significant differences in demographics and clinical characteristics between the subgroups comparing those with mild to those with severe asthma. However, the group with moderate compared to severe asthma showed fewer differences. Medications other than ICS, although differing between the mild, moderate and severe groups, were used in much smaller
proportions of subjects and were nearly the same for mild and moderate subgroups (Table S1 ). Table 2 provides sputum inflammatory cell differential percentages and counts/mL. Differences were observed in decreased macrophage % and increased bronchial epithelial cell % and cell count x 10 4 /mL for subjects in the severe asthma subgroup compared to mild asthma. There was a trend towards increased neutrophil % in the severe asthma subgroup (P = .073), but no differences were found for lymphocytes or eosinophils. There were no sputum cell differences between moderate and severe subgroups ( Table 2) .
| Cellular characteristics
The difference between mild, moderate and severe groups for ICS use potentially altered sputum cell differentials. Therefore, the subjects in the mild and moderate subgroups were further stratified by no ICS or ICS use and examined for differences in sputum cell counts. (Only 1 severe asthma subject not on high dose ICS but receiving injected corticosteroid precluded similar stratification of the severe subgroup.) The only difference noted for ICS effect on sputum differential counts was for %eosinophils in the moderate subgroup; however, higher eosinophils were observed in those receiving ICS (no ICS: median eosinophils = 0.3% [0.001-2.1%]; +ICS:
median eosinophils: 1.5% [0.55-7.55%]; P = .005).
| Molecular characteristics
Inflammatory mediators of sputum were examined through broadspectrum assay of 75 cytokines, chemokines and growth factors. Eleven of these had measurable levels above the lower limit of detection in less than one-third of the entire subject cohort (in online repository Table S1 ) and were not analysed further. These 11 mediators did not differ for the presence or absence of signal between mild, moderate or severe subject cohorts. The remaining cytokines, chemokines and growth factors were individually tested for differences between subjects with mild or moderate asthma compared to severe asthma (Table 2 , those not significantly differing among severity groups are listed in Table S2 
| Cell and molecular associations
Cytokines, chemokines and growth factors were examined by multivariate regression for association with specific cell types found in sputum. Thirty-eight cytokines, chemokines and growth factors had significant associations with specific sputum cells, or more than 1 cell type, within the entire cohort (Table 3) . Only CCL3/MIP1a associated negatively with increased bronchial epithelial cell counts; the other cytokines, chemokines and growth factor associations were positive with increasing cell numbers. There were 26 cytokines, chemokines or growth factors showing no association with any specific cell type in the entire cohort, although a few had significant associations within mild, moderate or severe subgroups (Tables S4-S6 ). Greater than two-thirds of the significant associations (68%)
within the whole cohort were with a single cell type, and the rest occurred with 2 cell types in different combinations. Neutrophils, either alone (42%) or in combination with lymphocytes or bronchial epithelial cells, were the dominant cell type associated with increasing inflammatory mediator levels. Thirteen per cent of the cytokines, chemokines or growth factors were associated with lymphocytes only, 5% with macrophages only, 5% with bronchial epithelial cells only and 3% with eosinophils only. Some of these cell-molecular associations were expected from previous reports, 13, 20, 21, 37 but others, for example neutrophils with CCL5/RANTES or CCL2/MCP1, were novel associations (see Figures S1a-d , and S2a-c).
Cell-molecular associations in mild and moderate asthma subgroups were more numerous than in severe asthma subgroup (Tables   S4, S5 and S6), although these differences may be attributable to greater numbers of subjects in mild and moderate subgroups than in the severe asthma subgroup and to the reduction in subject numbers in each subgroup as compared to the whole cohort. Thirty of the 35 cytokines, chemokines or growth factors having significant cell associations in mild asthma were also observed in the entire cohort, but One clinical variable potentially altering cell-molecular associations is corticosteroid use, which differed between the asthma severity subgroups (see Table 1 ), although there was little indication that ICS use altered sputum cells. Therefore, multivariate regressions were repeated adding the independent categorical variable of ICS.
Only 4 cytokines showed altered cell associations, TNFSF10/TRAIL, CCL11/eotaxin, CXCL5/ENA78 and CXCL8/IL8, and for only 2 of these, CXCL8/IL8 and TNFSF10/TRAIL, were ICS, a significant independent variable (P = .023, and .025, respectively), but these R and P values for overall regression model; P values for individual cell count appear under cell type(s) which were significantly associated. All were positive associations with increasing cell count except for CCL3/MIP1a which was negatively associated with epithelial cell count ("neg" suffix).
mediators did not differ between the mild, moderate and severe subgroups (see Table 2 ).
Another approach was to examine whether associations occurred among the cytokines, chemokines and growth factors analysed.
| Molecular associations by factor analysis
Factor analysis was performed to determine which cytokines, chemokines and growth factors were strongly correlated, and therefore represented potential underlying molecular relationships or biologic pathways. Factor analysis included 43 cytokines, chemokines and growth factors for which all of 140 subjects had measurable levels ( Table 4) . These 43 cytokines, chemokines and growth factors grouped onto Factors 1-10; 16 of the mediators showed association with 2 separate factors (the higher eigenvalue indicated by bold font in were not included in factor analysis because measurable levels were not observed in all 140 subjects.
Cytokines associated with Factors 1-7 were examined in string_-db.org 36 to investigate whether the proteins on each factor corresponded to recognized linkage groups as independent confirmation of mediator groups identified in factor analysis (see Figure 1A -G).
String did not recognize or indicate linkages for certain proteins in factor group 2 (TNFSF10), group 3 (TGF-a and IL-16) and group 4 (EGF and CCL15). However, TNFSF10, TGF-a, EGF and IL-16 were interconnected with other proteins on factor groups 7, 2, 2 and 6, respectively. Only CCL15 (Factor group 4) failed to interact with constituents on either its primary factor or any other factor. All other proteins on Factors 1-7 appeared to link with at least one other component, forming networks for each factor group.
| DISCUSSION
Broad assessment of 75 inflammatory mediators in induced sputum from 158 subjects with a spectrum of asthma severity revealed the following: (i) significant differences in cytokines, chemokines and growth factors between mild and severe asthma subgroups but few differences between moderate and severe asthma subgroups; (ii) inflammatory proteins predominantly associated with increasing numbers of neutrophils, but differences in specific cell-molecular associations were observed between mild, moderate and severe asthma; and (iii) complex patterns of associations between Th1, Th2, Th9 and Th17 inflammatory proteins were identified by factor analysis and confirmed in String v10. 36 Despite differences between asthma subgroups, analysis of the whole cohort by factor analysis identified mediators associated with innate inflammation and repair processes on the first 2 primary factors.
Severe asthma may be characterized by different inflammatory characteristics compared to less severe mild and moderate asthma. 6, 7 Our results found the severe subgroup compared to the mild Th9-IL-9 Anti-inflammatory-CCL21/6Ckine
Factor 10
Th2-CCL8/MCP2, CCL13/MCP4
Those that may be induced by other proteins identified on the same factor are noted in parentheses. Cytokines, chemokines or growth factors observed on 2 different factors are presented in bold font for the stronger association (higher Eigenvalue).
F I G U R E 1 Cytokines, chemokines and growth factors identified with each factor in Table 4 were examined in string_db.org for interactions. Only CCL15 (on Factor 4) did not interact with any other constituents on different factors. TNFSF10, TGF-a and IL-16, and EGF, lacked interactions with proteins on Factors 2, 3 and 4, but were interactive on Factors 7, 2, 6 and 2, respectively subgroup had fewer sputum macrophages and increased bronchial epithelial cells than observed in mild asthma, but no sputum cell differences compared to moderate asthma. Lymphocytes, eosinophils and neutrophils did not significantly differ across severity groups.
However, 13 inflammatory cytokines, chemokines and growth factors differed in concentration between mild and severe subgroups; only 4 of these also differed between moderate and severe. These results may reflect that those with "moderate" asthma may overlap with "severe" classification and, or that the smaller N for the severe asthma subgroup produced less power to reveal differences as observed in other, larger cohorts. 6,28 U-BIOPRED's cluster groups with severe asthma had 9 sputum proteins increased compared to moderate asthma, but 5 of these were elevated in subjects with significant smoking packyear history which may contribute to the differences. 28 In our severe subgroup, both Th1 mediators, IFN-c and TNF-a, and Th2 cytokines, IL-4 and IL-9, were elevated. It should be noted that these samples and analyses characterize subjects during baseline periods of stable asthma and 62% of subjects received inhaled corticosteroid therapy which, in responsive subjects, suppresses Th2 adaptive inflammation. 38 Thus, Th1 immune mediators might predominate over Th2, but both were observed in subjects with severe asthma.
We have previously observed decreased lung function associated with increased bronchial epithelial cells in sputum from a larger cohort, 7 suggesting greater airway injury, lack of repair or remodelling as asthma severity increases. In addition to increased bronchial epithelial cells, the sputum for the current severe subgroup had more than twofold increased PDGF BB , which contributes to airway smooth muscle proliferation 39 and fibroblast collagen I production. 40 However, VEGF, another growth factor considered important in airway repair and remodelling, 20 showed a trend towards reduction in our severe group compared to mild.
Unsupervised cluster analysis including blood and sputum eosinophil and neutrophil cell counts with clinical variables for a larger group of SARP subjects observed that sputum neutrophil % was a significant variable for determining cluster assignment associated with more severe asthma. 6 | 795 inflammation, 13 as represented by IL-5 and IL-13 on Factor 6.
String_db.org confirmed linkage groups for the majority of mediators identified with each factor, thereby providing independent validation of the factor analysis results. Thus, factor analysis of these cytokines, chemokines and growth factors observed in subjects with a spectrum of asthma severity confirms current understanding of inflammatory mediator relationships, but in addition, indicates novel interactions and underscores complex patterns of Th1, Th2, Th9 and Th17 inflammation combined.
As indicated in the introduction, other recent studies in severe asthma have reported mainly transcriptomic gene expression data from various cell sources, including sputum, epithelial brush and biopsy, [24] [25] [26] [27] [28] in addition to more limited information for protein analysis. Proteins identified by Somascan in sputum supernatants of U-BIOPRED subjects presented only mild/moderate asthma, or severe asthma data (either smoking or not) compared to healthy controls subjects, without comparison between mild/moderate and severe asthma groups. 25 They noted upregulation of IL-1 receptor family members by gene expression in those with severe asthma 25 not only compared to healthy controls but also to the mild/moderate asthma group.
Although we do not have gene expression data from our subjects, IL1b protein was significantly associated with sputum neutrophils in our severe subgroup, but not in mild or moderate subgroups.
The clinical importance of this study is not only the differences observed for subjects with severe asthma, but the identification of multiple inflammatory pathways existing simultaneously in airways for patients with a broad range of asthma severity. The implication from these observations is that assessment of a single biomarker may mislead in determination of airway inflammatory status and could fail to recognize patient response to therapeutic interventions.
A multi-assessment approach would be better even for trials which target 1 specific component of an immune pathway.
In summary, sputum cytokines, chemokines and growth factors differed between mild and severe asthma subjects, mainly representing Th1 and Th17 inflammation linked to increased neutrophils with few Th2 inflammatory mediators associated with eosinophils. Factor analysis found cytokines, chemokines and growth factors separating into 10 groups comprised of complex associations of Th1, Th2, Th9
and Th17 inflammatory and anti-inflammatory mediators. These results emphasize the multifactorial character of overlapping inflammatory pathways in asthma and highlight differences for more severe asthma.
